|
1
|
Okada R, Shimada H, Tagawa M, Matsushita
K, Otsuka Y, Kuwajima A and Kaneko H: Profiling of serum
autoantibodies in Japanese patients with hepatocellular carcinoma.
Toho J Med. 3:84–92. 2017.
|
|
2
|
Okada R, Otsuka Y, Wakabayashi T, Shinoda
M, Aoki T, Murakami M, Arizumi S, Yamamoto M, Aramaki O, Takayama
T, et al: Six autoantibodies as potential serum biomarkers of
hepatocellular carcinoma: A prospective multicenter study. Int J
Cancer. 147:2578–2586. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hoshino I, Nagata M, Takiguchi N, Nabeya
Y, Ikeda A, Yokoi S, Kuwajima A, Tagawa M, Matsushita K, Satoshi Y
and Hideaki S: Panel of autoantibodies against multiple
tumor-associated antigens for detecting gastric cancer. Cancer Sci.
108:308–315. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hoshino I, Nabeya Y, Takiguchi N, Gunji H,
Ishige F, Iwatate Y, Shiratori F, Yajima S, Okada R and Shimada H:
Prognostic impact of p53 and/or NY-ESO-1 autoantibody induction in
patients with gastroenterological cancers. Ann Gastroenterol Surg.
4:275–282. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ushigome M, Nabeya Y, Soda H, Takiguchi N,
Kuwajima A, Tagawa M, Matsushita K, Koike J, Funahashi K and
Shimada H: Multi-panel assay of serum autoantibodies in colorectal
cancer. Int J Clin Oncol. 23:917–923. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kabashima A, Shimada S, Shimokawa M,
Akiyama Y, Tanabe M and Tanaka S: Molecular and immunological
paradigms of hepatocellular carcinoma: Special reference to
therapeutic approaches. J Hepatobiliary Pancreat Sci. 28:62–75.
2021. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tan HT, Low J, Lim SG and Chung MC: Serum
autoantibodies as biomarkers for early cancer detection. FEBS J.
276:6880–6904. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lacombe J, Mangé A and Solassol J: Use of
autoantibodies to detect the onset of breast cancer. J Immunol Res.
2014:5749812014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Di Sabatino A, Biagi F, Lenzi M, Frulloni
L, Lenti MV, Giuffrida P and Corazza GR: Clinical usefulness of
serum antibodies as biomarkers of gastrointestinal and liver
diseases. Dig Liver Dis. 49:947–956. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pongratz G, Frieser R, Brinks R, Schneider
M, Hartung W, Fleck M and Ehrenstein B: Association between
autoantibody level and disease activity in rheumatoid arthritis is
dependent on baseline inflammation. Clin Exp Rheumatol. 38:691–698.
2020.PubMed/NCBI
|
|
11
|
Jodeleit H, Milchram L, Soldo R,
Beikircher G, Schönthaler S, Al-Amodi O, Wolf E, Beigel F,
Weinhäusel A, Siebeck M and Gropp R: Autoantibodies as diagnostic
markers and potential drivers of inflammation in ulcerative
colitis. PLoS One. 15:e02286152020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Peng B, Huang X, Nakayasu ES, Petersen JR,
Qiu S, Almeida IC and Zhang JY: Using immunoproteomics to identify
alpha-enolase as an autoantigen in liver fibrosis. J Proteome Res.
12:1789–1796. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
He X, Hong Y, Wang X, Zhang X, Long J, Li
H, Zhang B, Chen S, Liu Q, Li H, et al: Identification and clinical
significance of an elevated level of serum aminoacylase-1
autoantibody in patients with hepatitis B virus-related liver
cirrhosis. Mol Med Rep. 14:4255–4262. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zheng SX, Xiang BD, Long JM, Qu C, Mo ZJ,
Li K, Zhuang Y, Lv ZL and Zhou SF: Diagnostic value of serum SMP30
and Anti-SMP30 antibody in hepatocellular carcinoma. Lab Med.
49:203–210. 2018.PubMed/NCBI
|
|
15
|
Kruger FC, Daniels CR, Kidd M, Swart G,
Brundyn K, van Rensburg C and Kotze M: APRI: A simple bedside
marker for advanced fibrosis that can avoid liver biopsy in
patients with NAFLD/NASH. S Afr Med J. 101:477–480. 2011.PubMed/NCBI
|
|
16
|
Sumida Y, Yoneda M, Hyogo H, Itoh Y, Ono
M, Fujii H, Eguchi Y, Suzuki Y, Aoki N, Kanemasa K, et al:
Validation of the FIB4 index in a Japanese nonalcoholic fatty liver
disease population. BMC Gastroenterol. 12:22012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Brierley JD, Gospodarowicz MK and
Wittekind CH: TNM classification of malignant tumors. UICC
International Union Against Cancer; 8th edition. New York, USA: pp.
90–93. 2016
|
|
18
|
Makuuchi M and Kokudo N: Clinical practice
guidelines for hepatocellular carcinoma: The first evidence based
guidelines from Japan. World J Gastroenterol. 12:828–829. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kubota K, Makuuchi M, Kusaka K, Kobayashi
T, Miki K, Hasegawa K, Harihara Y and Takayama T: Measurement of
liver volume and hepatic functional reserve as a guide to
decision-making in resectional surgery for hepatic tumors.
Hepatology. 26:1176–1181. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jang ES, Jeong SH, Kim JW, Hoi YS,
Leissner P and Brechot C: Diagnostic performance of
alpha-fetoprotein, protein induced by vitamin K absence,
osteopontin, Dickkopf-1 and Its combinations for hepatocellular
carcinoma. PLoS One. 11:e01510692016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhou JW, Li Y, Yue LX, Luo CL, Chen Y and
Zhang JY: Autoantibody response to Sui1 and its tissue-specific
expression in hepatocellular carcinoma. Tumour Biol. 37:2547–2553.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nanami T, Hoshino I, Ito M, Yajima S,
Oshima Y, Suzuki T, Shiratori F, Nabeya Y, Funahashi K and Shimada
H: Prevalence of autoantibodies against Ras-like GTPases, RalA, in
patients with gastric cancer. Mol Clin Oncol. 13:282020.PubMed/NCBI
|
|
23
|
Nanami T, Shimada H, Yajima S, Oshima Y,
Matsushita K, Nomura F, Nagata M, Tagawa M, Otsuka S, Kuwajima A
and Kaneko H: Clinical significance of serum autoantibodies against
Ras-like GTPases, RalA, in patients with esophageal squamous cell
carcinoma. Esophagus. 13:167–172. 2016. View Article : Google Scholar
|
|
24
|
Kubota Y, Ogata H, Otsuka S, Kuwajima A,
Saito F and Shimada H: Presence of autoantibodies against Ras-like
GTPases in Serum-in stage I/II breast cancer. Toho J Med.
3:125–130. 2017.
|
|
25
|
Sun H, Shi JX, Zhang HF, Xing MT, Li P,
Dai LP, Luo CL, Wang X, Wang P, Ye H, et al: Serum autoantibodies
against a panel of 15 tumor-associated antigens in the detection of
ovarian cancer. Tumour Biol. 39:10104283176991322017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu W, Li Y, Wang B, Dai L, Qian W and
Zhang JY: Autoimmune response to IGF2 mRNA-binding protein 2
(IMP2/p62) in breast cancer. Scand J Immunol. 81:502–507. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bauer A and Habior A: Detection of
autoantibodies against nucleoporin p62 in Sera of patients with
primary biliary cholangitis. Ann Lab Med. 39:291–298. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang J, Jiao S, Kang J, Li R and Zhang G:
Application of serum NY-ESO-1 antibody assay for early SCLC
diagnosis. Int J Clin Exp Pathol. 8:14959–14964. 2015.PubMed/NCBI
|
|
29
|
Zhang Z, Li FF, Lu MD, Zhang SX and Li YX:
Anti-NY-ESO-1 autoantibody may be a tumor marker for intrahepatic
cholangiocarcinoma. Oncotarget. 8:103283–103289. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Herkel J, Modrow JP, Bamberger S, Kanzler
S, Rotter V, Cohen IR and Lohse AW: Prevalence of autoantibodies to
the p53 protein in autoimmune hepatitis. Autoimmunity. 35:493–496.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Himoto T, Yoneyama H, Kurokohchi K, Inukai
M, Masugata H, Goda F, Haba R, Watanabe S, Senda S and Masaki T:
Clinical significance of autoantibodies to p53 protein in patients
with autoimmune liver diseases. Can J Gastroenterol. 26:125–129.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Okada R, Shimada H, Otsuka Y, Tsuchiya M,
Ishii J, Katagiri T, Maeda T, Kubota Y, Nemoto T and Kaneko H:
Serum p53 antibody as a potential tumor marker in extrahepatic
cholangiocarcinoma. Surg Today. 47:1492–1499. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ito M, Hiwasa T, Oshima Y, Yajima S,
Suzuki T, Nanami T, Sumazaki M, Shiratori F, Funahashi K, Li SY, et
al: Association of serum anti-PCSK9 antibody levels with favorable
postoperative prognosis in esophageal cancer. Front Oncol.
11:7080392021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang Z, Gou W, Liu M, Sang W, Chu H and
Zhang W: Expression of P53 and HSP70 in chronic hepatitis, liver
cirrhosis, and early and advanced hepatocellular carcinoma tissues
and their diagnostic value in hepatocellular carcinoma: An
immunohistochemical study. Med Sci Monit. 21:3209–3215. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang K, Chen Y, Liu S, Qiu S, Gao S, Huang
X, Zhang J, Peng X, Qiani W and Zhang JY: Immunogenicity of Ra1A
and its tissue-specific expression in hepatocellular carcinoma. Int
J Immunopathol Pharmacol. 22:735–743. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu J, Li W, Deng M, Liu D, Ma Q and Feng
X: Immunohistochemical determination of p53 protein overexpression
for predicting p53 gene mutations in hepatocellular carcinoma: A
meta-analysis. PLoS One. 11:e01596362016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen L, Liu Y, Zhang Q, Zhang M, Han X, Li
Q, Xie T, Wu Q and Sui X: p53/PCDH17/Beclin-1 proteins as
prognostic predictors for urinary bladder cancer. J Cancer.
10:6207–6216. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bian C, Li Z, Xu Y, Wang J, Xu L and Shen
H: Clinical outcome and expression of mutant P53, P16, and Smad4 in
lung adenocarcinoma: A prospective study. World J Surg Oncol.
13:1282015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kashofer K and Regauer S: Analysis of full
coding sequence of the TP53 gene in invasive vulvar cancers:
Implications for therapy. Gynecol Oncol. 146:314–318. 2017.
View Article : Google Scholar : PubMed/NCBI
|
